




PHARMACEUTICAL 2018

Propanc Biopharma Inc.
Rank 338 of 342





PHARMACEUTICAL 2018

Propanc Biopharma Inc.
Rank 338 of 342

The relative strengths and weaknesses of Propanc Biopharma Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Propanc Biopharma Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 775% points. The greatest weakness of Propanc Biopharma Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 411% points.

The company's Economic Capital Ratio, given in the ranking table, is -617%, being 662% points below the market average of 46%.

Input Variable	Value in 1000 USD
Assets, Current	82
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	5,537
Liabilities, Non-Current	0
Other Assets	2.3
Other Compr. Net Income	-273
Other Expenses	-277
Other Liabilities	0
Other Net Income	-2,433
Other Revenues	0
Property and Equipment	11
Research and Development	972
Selling, General and Administrative Expense	4,739

Output Variable	Value in 1000 USD
Assets	95
Liabilities	5,537
Expenses	5,435
Revenues	0
Stockholders Equity	-5,442
Net Income	-7,868
Comprehensive Net Income	-8,004
Economic Capital Ratio	-617%